NuCana Compliant with All Nasdaq Continued Listing Criteria

Core Viewpoint - NuCana plc has confirmed compliance with Nasdaq's continued listing criteria, closing a previously disclosed listing matter, and is well-positioned for future operations and clinical milestones [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which enhances the efficacy and safety of widely prescribed chemotherapy agents [3]. - The company's pipeline includes NUC-7738, currently in Phase 2 trials for advanced solid tumors and melanoma, and NUC-3373, being evaluated in a Phase 1b/2 study for advanced solid tumors and lung cancer [3]. Financial Position - The company anticipates that its existing cash resources, bolstered by proceeds from an ATM offering, will be sufficient to fund operations into 2029 [2].